This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
HHS’s 340B drug discount program is set to shift to a rebate model on New Year’s Day. But a lawsuit and temporary restraining order filed by the AHA and others may block the change from going live on time.
Will there or won’t there be a federal moratorium on state-level regulation of AI?That’s only one question healthcare stakeholders are asking as 2025’s time begins running out.
Advanced AI technologies are starting to play a bigger role in TAVR care, helping cardiologists plan ahead, make critical decisions and predict potential complications. Looking to the future, though, it is clear this is just the beginning.
Hospitals could be turning away high-risk heart patients to help their TAVR programs receive a higher ranking, according to new research published in JACC: Cardiovascular Interventions.
Less than a third of companies employing tech-equipped knowledge workers have a formal AI strategy in place. And “dangerous divides” separate such workers from the leaders to whom they ultimately report.
More than 60% of adults in the United States are expected to have at least one form of cardiovascular disease by 2050, according to new data published by the American Heart Association. Fortunately, evidence does suggest that healthier lifestyles are starting to become more common as time goes on.
A word to the wise among leaders of hospitals and health systems: Don’t wait on the government to tell you how to keep healthcare AI on track and healthcare providers up to speed.
According to a new proposal, using AI to evaluate CCTA results and quantify plaque buildup is “reasonable and medically necessary” in certain clinical scenarios.